Keros Therapeutics (KROS) CEO exercises options for 55,000 shares
Jasbir Seehra, CEO of Keros Therapeutics (KROS), exercised employee stock options to acquire 55,000 shares of common stock at $0.30 per share on April 2, 2026. Following this transaction, his direct ownership increased to 440,708 shares of common stock. The options were immediately exercisable and had an expiration date of March 25, 2028.
JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS
JPMorgan Chase & Co. significantly increased its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 260.8% in the third quarter, acquiring an additional 124,287 shares and now owning 171,941 shares valued at $2.72 million. This increase comes despite Keros Therapeutics missing its Q3 earnings and revenue expectations, reporting an EPS of ($0.86) against a consensus of ($0.49) and revenue of $0.39 million versus an expected $3.66 million. The biopharmaceutical company has a consensus "Hold" rating from analysts with a price target of $21.86, while the stock currently trades near $12.
Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC significantly increased its stake in Keros Therapeutics (NASDAQ: KROS) by 1,420.6% in the fourth quarter, acquiring an additional 92,212 shares, bringing its total to 98,703 shares valued at approximately $2.01 million. This increase occurred despite Keros Therapeutics reporting a weaker-than-expected quarter on March 4, with an EPS of ($0.86) against a consensus of ($0.49) and an 87.2% year-over-year revenue decline. The stock currently trades around $12, holding a consensus "Hold" rating from analysts with an average price target of $21.86.
The Technical Signals Behind (KROS) That Institutions Follow
This article analyzes the technical signals for Keros Therapeutics Inc. (NASDAQ: KROS) for institutional tracking. It highlights near-term strong sentiment, mid-term neutrality, and long-term positive bias, along with warning of elevated downside risk due to a lack of long-term support signals. The article also provides AI-generated trading strategies with specific entry, target, and stop-loss levels for different risk profiles.
KROS Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for KROS, highlighting past quarterly results and future forecasts. It details revenue and EPS figures for recent quarters, including specific dates and surprise percentages. The article also covers analyst estimates for 2026/Q1, stock price correlation with forecast revisions, and historical stock price reactions around earnings reports to help investors with trading strategies.
[144] Keros Therapeutics, Inc. SEC Filing
This SEC filing (Form 144) for Keros Therapeutics, Inc. (KROS) reports a proposed sale of 45,057 shares of common stock with an aggregate market value of $497,429.28. The shares were acquired on April 13, 2020, through an IPO. The filing indicates a neutral impact and sentiment.
Keros Therapeutics (KROS) awards 80,000 stock options to Chief Legal Officer
Keros Therapeutics announced that its Chief Legal Officer, Esther Cho, has been granted 80,000 employee stock options. These options have an exercise price of $15.52 per share and will expire on February 23, 2036. The vesting schedule begins on February 24, 2027, with the remaining options vesting quarterly, contingent on her continued employment.
Vanguard disaggregates holdings; reports 0 KROS shares (KROS)
The Vanguard Group has filed an amended Schedule 13G/A for Keros Therapeutics Inc. (KROS), reporting 0 shares beneficially owned, representing 0% of Keros common stock. This change follows an internal realignment on January 12, 2026, where certain subsidiaries will now report their holdings separately, in accordance with SEC Release No. 34-39538. The filing indicates that Vanguard no longer holds direct beneficial ownership over these securities.
KROS SEC Filings - Keros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to SEC filings for Keros Therapeutics (KROS), including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights recent filings detailing ownership changes, executive stock options, tender offers for share repurchase, and quarterly financial results, emphasizing the company's focus on TGF-ß pathway therapeutics. The platform also offers AI-powered summaries of these documents.
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from S&P Biotechnology Select Industry Index
Keros Therapeutics, Inc. (NasdaqGM:KROS) has been removed from the S&P Biotechnology Select Industry Index. The company is a clinical-stage biopharmaceutical firm focusing on developing therapies for disorders related to dysfunctional signaling of the transforming growth factor-beta (TGF-B) family of proteins. Recent news includes collaborations for Lou Gehrig's disease treatment trials, additional clinical data, and earnings reports.
Precision Trading with Keros Therapeutics Inc. (KROS) Risk Zones
This article analyzes Keros Therapeutics Inc. (KROS), highlighting divergent sentiment across trading horizons and suggesting choppy conditions. It provides AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategies with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis, showing support and resistance levels for near-term, mid-term, and long-term periods.
KROS SEC Filings - Keros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Keros Therapeutics, Inc. (KROS) SEC filings, including 10-K, 10-Q, and 8-K forms, offering investors detailed regulatory disclosures on clinical programs, financial conditions, and corporate events. It highlights recent filings detailing insider ownership, material events, quarterly earnings, and significant trading activity by investment firms like ADAR1 Capital Management. The platform also offers AI-powered tools to summarize complex filings for easier understanding.
KROS stock: What to know about Rinvatercept in DMD
The article discusses KROS stock and provides information about Rinvatercept, a treatment related to Duchenne Muscular Dystrophy (DMD).
KROS stock: What to know about Rinvatercept in DMD
The article discusses Keros Therapeutics (KROS) and its drug Rinvatercept, which is being studied for its potential to treat Duchenne muscular dystrophy (DMD). Rinvatercept is designed to increase lean muscle mass by targeting ligands in the TGF-beta superfamily. The company is currently evaluating the drug in early-stage clinical trials.
Can Keros Therapeutics Rinvatercept stand out in the DMD market?
This article analyzes Keros Therapeutics' drug Rinvatercept and its potential to differentiate itself in the Duchenne muscular dystrophy (DMD) market. It will likely discuss the drug's mechanism of action, clinical trial progress, and competitive landscape. The aim is to assess whether Rinvatercept can carve out a unique and successful position among existing and developing DMD treatments.
KROS: Does the Discounted Book Value Represent a Value Trap?
Keros Therapeutics (KROS) saw a significant revenue increase in 2025, primarily from a one-time licensing deal with Takeda, raising questions about the sustainability of its earnings. Despite trading below book value and having a strong cash runway extending into 2028, the company faces risks due to its reliance on partnership economics, lack of product sales, and intense competition in the Duchenne muscular dystrophy market. The article discusses whether this presents a value opportunity or a potential value trap for investors.
KROS Stock: Key Information on Rinvatercept for DMD
Keros Therapeutics is advancing rinvatercept (KER-065) for Duchenne muscular dystrophy (DMD), targeting the TGF-β pathway to improve muscle and bone health. The drug recently received FDA orphan drug designation and showed positive Phase I results, leading to plans for a Phase II trial in Q2 2026. While promising, the company's focus on this single program presents a concentrated risk, and its success will depend on meeting development targets and navigating the competitive DMD landscape.
KROS: Is the Discount Book Value a Value Trap?
Keros Therapeutics (KROS) saw a significant revenue increase in 2025 due to a licensing deal with Takeda, but this revenue is largely one-time and not yet supported by product sales. The company's shares trade at a discount to book value, prompting questions about whether it's a value investment or a value trap. Keros has a cash runway into 2028 and has reduced its cost structure, but future financials and the success of its lead program, rinvatercept, will determine its long-term viability.
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Keros Therapeutics (KROS) is focusing its 2026 pipeline on rinvatercept, with a Phase II study for Duchenne muscular dystrophy (DMD) expected to start in Q2 2026 and regulatory discussions for a Phase II ALS study planned for H2 2026. The company's recent Phase I data supports the mechanism of action with positive changes in muscle, fat, and bone. Despite a competitive DMD landscape and current lack of product sales, Keros aims for disciplined progress through upcoming milestones, backed by $287.4 million in cash at the end of 2025.
KROS Stock: What to Know About Rinvatercept in DMD
Keros Therapeutics (KROS) is advancing its lead asset, rinvatercept (KER-065), for Duchenne muscular dystrophy (DMD). The company aims to improve muscle and bone outcomes by modulating TGF-beta pathway ligands, providing a differentiated approach compared to standard glucocorticoid treatments. Rinvatercept has received orphan drug designation and is slated for a Phase II trial start in Q2 2026, building on positive Phase I data showing muscle, fat, and bone benefits, though intense competition exists from companies like Sarepta and PTC Therapeutics.
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update
Keros Therapeutics (NASDAQ:KROS) experienced a 14.8% decrease in short interest in February, with 2,031,197 shares shorted, representing 8.6% of its float. Despite this, the company missed its quarterly earnings expectations, reporting an EPS of ($0.86) against an anticipated ($0.49), and revenue of $0.39M, significantly below estimates. Institutional investors, including Western Standard LLC and Renaissance Technologies LLC, have shown increased interest, with institutions collectively owning 71.56% of the company's stock.
Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics
The Myelofibrosis market is projected to grow significantly, from USD 2,602 million in 2025 to USD 5,368 million by 2034, at a CAGR of 9.0%. This growth is driven by increasing prevalence, awareness, and the launch of new pipeline products from key companies such as Lynk Pharmaceuticals, Bristol-Myers Squibb, and Keros Therapeutics. The United States currently holds the largest market share, with JAKAFI/JAKAVI leading in treatment, while several new therapies are in various stages of development.
Keros Therapeutics (KROS) director submits initial Form 3 ownership
Keros Therapeutics, Inc. director Charles W. Newton has filed an initial statement of beneficial ownership on Form 3. This filing establishes him as a reporting insider and records his starting position for future ownership and transaction disclosures. The Form 3 itself does not report any share transactions but serves to increase transparency for investors regarding future insider activity.
Director adds Keros Therapeutics (NASDAQ: KROS) shares under 10b5-1 plan
Keros Therapeutics director Jean Jacques Bienaime purchased 2,000 shares of common stock at a weighted average price of $11.21 per share on March 9, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, bringing Bienaime's direct holdings to 7,450 shares. The filing indicates a positive sentiment regarding the scheduled purchase.
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Keros Therapeutics announced additional data from its Phase 1 clinical trial of rinvatercept (KER-065) in healthy volunteers, presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. The data reinforced rinvatercept's potential for neuromuscular diseases, showing it was well-tolerated and led to increased muscle mass, decreased fat mass, and improved bone mineral density, consistent with activin and myostatin inhibition. Keros plans to advance rinvatercept into Phase 2 trials for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
Experimental drug boosts muscle and bone in early trial, eyed for DMD and ALS
Keros Therapeutics presented additional Phase 1 clinical data for rinvatercept (KER-065) showing it was well-tolerated and led to increased muscle mass and bone mineral density, and decreased fat mass in healthy volunteers. These findings, along with proteomic evidence of target engagement, will guide the drug's development for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). The company plans to advance rinvatercept into Phase 2 clinical trials for both DMD and ALS.
Personalized ALS trial to test Keros rinvatercept at Mass General
Keros Therapeutics announced a collaboration with Massachusetts General Hospital and the Sean M. Healey & AMG Center for ALS to design a Phase 2 clinical trial for rinvatercept in ALS patients. This partnership will utilize biomarker-driven personalized trial methods within the Healey ALS MyMatch program to identify optimal patient subgroups for experimental therapies. The goal is to accelerate the development of new ALS treatments by deepening the understanding of biological effects and pinpointing the most suitable populations for later-stage trials.
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Keros Therapeutics announced additional clinical data from its Phase 1 trial of rinvatercept (KER-065) at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. The data reinforced rinvatercept's potential to treat neuromuscular diseases like Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), showing improvements in body composition, mitigation of fibrosis and inflammation, and beneficial effects in preclinical models. Keros plans to advance the rinvatercept program into two Phase 2 clinical trials for DMD and ALS.
Keros Therapeutics to Test Rinvatercept in Phase 2 ALS Trial with Mass General; Phase 1 Data Presented
Keros Therapeutics is partnering with Massachusetts General Hospital for a Phase 2 trial of rinvatercept in ALS, utilizing the Healey ALS MyMatch program for biomarker-driven patient matching. The company also presented additional Phase 1 data supporting rinvatercept's mechanism, showing it was well-tolerated and linked to increased muscle mass and bone density, aiming to advance the drug into two Phase 2 trials for DMD and ALS.
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
Keros Therapeutics has announced a collaboration with the Sean M. Healey & AMG Center for ALS to design a Phase 2 clinical trial for rinvatercept in patients with amyotrophic lateral sclerosis (ALS). The trial will evaluate rinvatercept within the Healey ALS MyMatch program, which uses biomarker-driven personalized approaches to accelerate the development of ALS therapies. Keros believes rinvatercept has the potential to preserve muscle strength and function, and improve the quality of life for ALS patients by targeting myostatin and activin A.
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Keros Therapeutics announced new clinical data from its Phase 1 trial of rinvatercept (KER-065) in healthy volunteers, presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. The data reinforced rinvatercept's therapeutic potential, showing positive effects on body composition and demonstrating target engagement consistent with its mechanism of action. Keros plans to advance rinvatercept into Phase 2 trials for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
Keros Therapeutics announced a collaboration with the Sean M. Healey & AMG Center for ALS at Mass General Brigham to evaluate rinvatercept in a Phase 2 clinical trial for amyotrophic lateral sclerosis (ALS). This collaboration is part of the ALS MyMatch program, which uses biomarker-driven personalized trial approaches to accelerate the development of new therapies. Rinvatercept, a novel ligand trap, is designed to improve muscle strength and function by inhibiting negative regulators of muscle and bone mass.
Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Keros Therapeutics (NASDAQ:KROS) from a "hold" to a "sell" rating on Saturday, following a weak quarterly earnings report where the company missed EPS and revenue expectations. Despite this, the overall analyst consensus for KROS remains a "Hold" with an average price target of $21.86, based on ratings from ten firms. The company's stock opened at $11.30, significantly below its 1-year high, and institutional investors hold approximately 71.6% of its shares.
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
Keros Therapeutics is developing rinvatercept (KER-065) for Duchenne muscular dystrophy (DMD) to promote muscle regeneration and strength by inhibiting TGF-β ligands. The company plans to start a Phase II trial for DMD in Q1 2026 and holds orphan drug designation for KER-065, positioning it against established players like Sarepta Therapeutics and PTC Therapeutics in a competitive therapeutic area. Despite strong competition, Keros Therapeutics is redirecting resources towards rinvatercept after discontinuing another program, and its stock appears undervalued based on its price/book ratio, while analysts project significant losses for 2026 and 2027.
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
Keros Therapeutics (KROS) is developing rinvatercept to treat Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), focusing on inhibiting TGF-ß ligands to promote muscle and bone health. While rinvatercept has received orphan drug designation for DMD and is moving into Phase II trials, KROS faces significant competition from established players like Sarepta Therapeutics and PTC Therapeutics in the challenging DMD market. Despite competitive pressures and a current Zacks Rank #3 (Hold), KROS's valuation appears inexpensive based on its price/book ratio, and the company is redirecting resources to advance rinvatercept's potential.
Can Keros Therapeutics' Rinvatercept Distinguish Itself in the DMD Marketplace?
Keros Therapeutics is developing rinvatercept (KER-065) as a potential treatment for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), focusing on blocking TGF-β ligands to improve muscle and bone health. While the DMD market is highly competitive with established players like Sarepta Therapeutics and PTC Therapeutics, Keros aims to differentiate its drug, which has orphan drug status and is entering Phase II trials. Despite strong competition, KROS stock performance shows a potentially undervalued asset based on its price-to-book ratio.
Keros Therapeutics Q4 Loss And Q1 Skewed EPS Challenge Bullish Profitability Narratives
Keros Therapeutics (KROS) reported a Q4 total revenue of US$0.4 million and a net income loss of US$23.5 million for FY 2025, despite the full year showing positive trailing earnings due to a very strong Q1. The company's overall revenue climbed from US$3.6 million in Q4 2024 to US$244.1 million, with basic EPS moving from a loss to a profit, though three of the last four quarters showed losses, raising questions about the sustainability of its profitability and challenging purely bullish narratives. Keros's low P/E ratio of 2.7x compared to industry averages and historical growth contrast sharply with analyst forecasts of significant declines in both earnings and revenue for the next three years.
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00
Wells Fargo & Company has lowered its price target for Keros Therapeutics (NASDAQ:KROS) from $23.00 to $20.00, while maintaining an "overweight" rating. This adjustment follows Keros Therapeutics' recent weak quarterly earnings, where the company missed revenue and EPS expectations significantly, leading to a substantial drop in share price. Despite diverse analyst opinions, the consensus rating for Keros Therapeutics remains "Hold" with an average target price of $21.86.
Keros Therapeutics Reports FY25 Results, Highlights Progress Across Hematology And Muscle Pipeline
Keros Therapeutics reported its financial results for the fourth quarter and full year 2025, showing a significant turnaround with a net income of $87.0 million for the year, primarily due to license revenue from Takeda. The company highlighted progress in its pipeline, including Rinvatercept for Duchenne muscular dystrophy and ALS, and Elritercept for cytopenias, with development costs for the latter now covered by Takeda. Keros also made corporate updates and possesses $287.4 million in cash and cash equivalents, expected to fund operations into the first half of 2028.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Keros Therapeutics announced its business highlights and financial results for Q4 and full year 2025, reporting a significant decrease in net loss for the quarter and net income for the year, largely due to a licensing agreement with Takeda. The company is strategically focused on advancing its lead product candidate, rinvatercept, into Phase 2 clinical trials for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). Keros also made board and leadership changes and expects its current cash and cash equivalents to fund operations into the first half of 2028.
KROS Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Keros Therapeutics, Inc. (KROS), including its income statement, balance sheet, and cash flow data derived from SEC filings. It highlights the company's strong financial health with high scores in profitability, growth, leverage, liquidity, cash flow, and returns for fiscal year 2025. Key metrics like revenue, net income, EPS, and various financial ratios are presented to demonstrate KROS's performance and stability.
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
Keros Therapeutics (KROS) reported a Q4 loss of $0.86 per share, missing the Zacks Consensus Estimate of a $0.49 loss, and revenues of $0.39 million, which fell short of the estimated $6.6 million. Despite surpassing EPS estimates three times in the last four quarters, the stock has declined by 34.2% year-to-date. The company currently holds a Zacks Rank #3 (Hold), indicating an expected in-line performance with the market.
Keros Therapeutics (NASDAQ: KROS) swings to 2025 profit on Takeda license windfall
Keros Therapeutics reported a significant financial turnaround in 2025, moving from a net loss of $187.4 million in 2024 to a net income of $87.0 million, primarily due to a license agreement with Takeda. The company's total revenue increased to $244.1 million, while research and development expenses decreased as Takeda assumed costs for elritercept. Keros ended 2025 with $287.4 million in cash, projected to fund operations into the first half of 2028, and is advancing its rinvatercept program into Phase 2 trials for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results
Keros Therapeutics (NASDAQ:KROS) recently announced its quarterly earnings, missing analyst consensus with an EPS of ($0.86) and revenue of $0.39 million. Despite the miss, the stock saw a 2.8% increase, trading at $13.77. Analyst ratings are mixed with a consensus "Hold" and high institutional ownership.
Biotech behind new DMD and ALS trials turns 2024 loss into 2025 profit
Keros Therapeutics (KROS) reported a significant financial turnaround, moving from a net loss of $187.4 million in 2024 to a net income of $87.0 million in 2025, largely due to a licensing agreement with Takeda. The biopharmaceutical company announced plans to initiate a Phase 2 trial for rinvatercept in Duchenne muscular dystrophy (DMD) in Q2 2026 and engage regulators for an ALS Phase 2 design in H2 2026. With $287.4 million in cash and equivalents at the end of 2025, Keros anticipates funding operations into the first half of 2028.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Keros Therapeutics reported significant business highlights and financial results for Q4 and full year 2025, showing a net income for the year largely due to a licensing agreement with Takeda. The company plans to advance its lead candidate, rinvatercept, into Phase 2 clinical trials for Duchenne muscular dystrophy and engage regulators for its use in amyotrophic lateral sclerosis. Keros also announced board and leadership changes and expects its current cash and cash equivalents to fund operations into the first half of 2028.
Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference
Keros Therapeutics presented at Oppenheimer's 36th Annual Healthcare Life Sciences conference, detailing plans to initiate a Duchenne muscular dystrophy (DMD) trial for rinvatercept (KER-065) this quarter and discuss a potential Phase II program in amyotrophic lateral sclerosis (ALS) with regulators later this year. The company also highlighted its partnership with Takeda for elritercept, which included a $200 million upfront payment and over $1.1 billion in potential milestones, and reported a strong financial position with cash runway into the first half of 2028. Rinvatercept is a modified activin receptor ligand trap designed to improve muscle regeneration and strength, with Phase I trials showing it was generally well-tolerated and produced pharmacology signals such as increased lean mass and improved bone markers.
Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference
Keros Therapeutics announced plans to initiate a Duchenne muscular dystrophy (DMD) trial for rinvatercept (KER-065) this quarter and to discuss a potential Phase II program in amyotrophic lateral sclerosis (ALS) with regulators later this year. The company's CEO, Jasbir Seehra, highlighted rinvatercept's mechanism as a modified activin-receptor ligand trap that inhibits negative muscle regulators and showed positive pharmacology signals in Phase I trials, including increased lean mass and improved bone markers. Keros also reviewed its partnership with Takeda for elritercept, which includes significant upfront payments and potential milestones.
Trading the Move, Not the Narrative: (KROS) Edition
This article provides an analysis of Keros Therapeutics Inc. (NASDAQ: KROS), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report suggests potential for lower levels if the current breakdown is sustained and points to elevated downside risk.
Keros Therapeutics Appoints Charles Newton to its Board of Directors
Keros Therapeutics (Nasdaq: KROS) announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026. Mr. Newton brings extensive experience in healthcare finance and capital markets, having served as CFO of Lyell Immunopharma and in leadership roles at major investment banks. Concurrently, Carl Gordon, Ph.D., CFA, will step down from the Board.
